Section of Medical Oncology

Medicine & Life Sciences

1. 130-nm albumin-bound paclitaxel 10%
2. Adenocarcinoma 17%
3. Adjuvant Chemotherapy 9%
4. B-Cell Chronic Lymphocytic Leukemia 11%
5. B-Cell Lymphoma 17%
6. Bendamustine Hydrochloride 17%
7. Bevacizumab 15%
8. Biomarkers 14%
9. Bone Marrow 9%
10. Bortezomib 14%
11. Breast 13%
12. Breast Neoplasms 77%
13. Brentuximab Vedotin 23%
14. Carboplatin 20%
15. Carcinoma 14%
16. Cetuximab 14%
17. Circulating Tumor DNA 15%
18. Cisplatin 18%
19. Clinical Trials 23%
20. Colorectal Neoplasms 9%
21. Combination Drug Therapy 9%
22. Confidence Intervals 16%
23. Cyclophosphamide 16%
24. DNA 16%
25. DNA Damage 8%
26. Docetaxel 21%
27. Doxorubicin 21%
28. Drug Therapy 58%
29. ErbB Receptors 10%
30. Erlotinib Hydrochloride 8%
31. Erythropoietin Receptors 11%
32. Estrogen Receptors 13%
33. Etoposide 12%
34. Everolimus 9%
35. Follicular Lymphoma 23%
36. gemcitabine 18%
37. Genes 16%
38. Genome 15%
39. Glioblastoma 18%
40. Growth 13%
41. Guidelines 17%
42. Head and Neck Neoplasms 10%
43. Heterografts 10%
44. High-Throughput Nucleotide Sequencing 8%
45. Hodgkin Disease 32%
46. Hormones 11%
47. Immunotherapy 27%
48. Lenalidomide 13%
49. Lung Neoplasms 27%
50. Lymphoma 23%
51. Lymphoma, Large B-Cell, Diffuse 26%
52. Macrophages 8%
53. Maintenance 13%
54. Mantle-Cell Lymphoma 33%
55. Maximum Tolerated Dose 12%
56. Melanoma 15%
57. Multiple Myeloma 12%
58. Mutation 28%
59. Neoadjuvant Therapy 10%
60. Neoplasm Metastasis 23%
61. Neoplasms 100%
62. Neurofibrosarcoma 10%
63. Neutropenia 10%
64. Nivolumab 10%
65. Non-Hodgkin's Lymphoma 32%
66. Non-Small Cell Lung Carcinoma 73%
67. Paclitaxel 19%
68. palbociclib 9%
69. Pancreatic Neoplasms 15%
70. PCI 32765 11%
71. pembrolizumab 18%
72. Pemetrexed 14%
73. Peripheral T-Cell Lymphoma 14%
74. Placebos 11%
75. Platinum 12%
76. Population 9%
77. Positron-Emission Tomography 10%
78. Prednisone 10%
79. Progression-Free Survival 46%
80. Prostatic Neoplasms 21%
81. Proteins 18%
82. Radiation 14%
83. Radiotherapy 27%
84. Recurrence 22%
85. Renal Cell Carcinoma 13%
86. Rituximab 43%
87. Safety 20%
88. Sarcoma 28%
89. Small Cell Lung Carcinoma 16%
90. Squamous Cell Carcinoma 14%
91. Squamous Cell Carcinoma of Head and Neck 16%
92. Stem Cell Transplantation 11%
93. Stem Cells 10%
94. Sunitinib 9%
95. Survival 62%
96. T-Lymphocytes 22%
97. Therapeutics 60%
98. Transplants 15%
99. Triple Negative Breast Neoplasms 24%
100. Vincristine 12%